 - Submitted New Drug Application NDA for trilaciclib in small cell lung cancer SCLC - Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch - Partnership for trilaciclib in China and global out-licensing of lerociclib net a combined 40 million in upfront payments, up to 486 million in milestone payments, plus potential royalties - Secured 100 million credit facility to support trilaciclib development and commercialization - Increasing cash guidance for FY 2020 to 185-200 million at year end - Management to host webcast and conference call today at 5:00 p.m. ETRESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 GLOBE NEWSWIRE -- G1 Therapeutics, Inc. Nasdaq: GTHX, a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2020.We made substantial progress on a number of fronts in the first half of 2020, and sharpened our focus on bringing trilaciclib to patients in 2021. By forging four strategic collaborations and securing a flexible credit facility, we have achieved three important objectives: positioning G1 for a strong commercial launch of trilaciclib in the United States, providing global access to our therapies, and securing non-dilutive capital to support the continued development of trilaciclib in additional indications, said Mark Velleca, M.D., Ph.D., Chief Executive Officer. We are now executing a comprehensive launch strategy for trilaciclib designed to raise awareness of the burden that chemotherapy-induced myelosuppression places on patients and the healthcare system, as well as implementing a robust development plan to evaluate the benefits of trilaciclib in additional tumor types and chemotherapy regimens.Regulatory, Clinical and Corporate Highlights NDA for trilaciclib in small cell lung cancer SCLC submitted in June 2020. Pending acceptance, the company expects to receive a PDUFA date assignment by the U.S. Food and Drug Administration FDA in August 2020. Trilaciclib has been assigned Breakthrough Therapy Designation by the FDA. Entered into co-promotion agreement with Boehringer Ingelheim for trilaciclib in SCLC in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in SCLC. G1 will lead marketing, market access and medical engagement initiatives, with Boehringer Ingelheim leading sales force engagement initiatives. G1 will book revenue and retain development and commercialization rights to trilaciclib press release here. Partnered with Simcere to develop and commercialize trilaciclib in Greater China. The company entered into an exclusive agreement with Simcere Pharmaceuticals Group for the development and commercialization of trilaciclib for all indications in Greater China mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the agreement, G1 received a 14 million upfront payment and is eligible to receive sales-based royalties and up to 156 million in potential milestone payments press release here. As part of this agreement, the company will collaborate with Simcere on future clinical trials. G1 and Simcere will be responsible for all development and commercialization costs in their respective territories. I-SPY 2 neoadjuvant breast cancer trial including trilaciclib initiated in 2Q20. Trilaciclib was selected for inclusion in the ongoing Phase 2 I-SPY 2 TRIALTM, based on compelling overall survival findings in a Phase 2 triple-negative breast cancer TNBC trial press release here. The I-SPY trial will generate data across a range of breast cancer subtypes that will allow the company to evaluate trilaciclib in combination with several broadly-used chemotherapy classes and an anti-PD-1 immunotherapy. Rintodestrant and Ibrance combination trial initiated in 2Q20. The company previously announced preliminary safety, tolerability and efficacy data on rintodestrant, its oral selective estrogen receptor degrader SERD press release here as monotherapy treatment for ER, HER2- breast cancer. Based on these findings, G1 initiated an additional arm of its ongoing Phase 12a trial to evaluate the combination regimen of rintodestrant and the CDK46 inhibitor Ibrance palbociclib. Palbociclib is being provided by Pfizer Inc. under a non-exclusive clinical supply agreement. Out-licensed global development and commercialization rights to lerociclib. The company entered into separate, exclusive agreements with EQRx rights for U.S., Europe, Japan, and all markets outside Asia-Pacific and Genor Biopharma rights for Asia-Pacific, excluding Japan for the development and commercialization of lerociclib in all indications. Combined, these agreements provided 26 million in upfront payments to G1, along with sales-based royalties and up to 330 million in potential milestone payments see press releases on EQRx agreement and Genor agreement. EQRx and Genor are responsible for all costs related to the development and commercialization of lerociclib in their respective territories. Out-licensed global development and commercialization rights to preclinical CDK2 inhibitor compounds. The company entered into an exclusive license agreement with ARC Therapeutics for global development and commercialization rights to its preclinical CDK2 inhibitor compounds. Under the terms of the agreement, G1 received an upfront payment and equity in ARC with an aggregate value of approximately 2.1 million. The company is also entitled to receive an additional milestone payment and sales-based royalties, and has right of first negotiation to re-acquire these assets. Secured flexible credit financing for up to 100 million. The company announced it had entered into a debt financing agreement for up to 100 million with Hercules Capital, Inc. G1 has accessed 20 million to support the development and commercialization of trilaciclib press release here.Second Quarter 2020 Financial Highlights and 2020 Guidance Cash Position: Cash and cash equivalents totaled 234.3 million as of June 30, 2020, compared to 269.2 million as of December 31, 2019. License Revenue: License revenues were 2.1 million for the second quarter of 2020, related to the license of CDK2 inhibitor compounds to ARC Therapeutics. Operating Expenses: Operating expenses were 33.0 million for the second quarter of 2020, compared to 32.6 million for the second quarter of 2019. GAAP operating expenses include stock-based compensation expense of 4.4 million for the second quarter of 2020, compared to 3.7 million for the second quarter of 2019. Research and Development Expenses: Research and development RD expenses for the second quarter of 2020 were 18.5 million, compared to 23.5 million for the second quarter of 2019. The decrease in RD expenses was primarily due to a decrease in clinical program costs of 3.4 million and regulatory filing reimbursement received during the second quarter of 2020 for 3.0 million, offset by an increase in costs for manufacturing active pharmaceutical ingredients. General and Administrative Expenses: General and administrative GA expenses for the second quarter of 2020 were 14.4 million, compared to 9.1 million for the second quarter of 2019. The increase in GA expenses was largely due to an increase in compensation due to additional headcount, increase in pre-commercialization activities, increase in medical affairs costs, and an increase in professional fees and other administrative costs necessary to support our operations. Net Loss: G1 reported a net loss of 31.2 million for the second quarter of 2020, compared to 30.7 million for the second quarter of 2019. 2020 Guidance: The company is increasing its previous financial guidance and expects to end 2020 with 185-200 million in cash and cash equivalents, up from previous guidance of 110-130 million. This guidance includes receipt of upfront payments from recent agreements, but does not include consideration of potential additional proceeds from partnerships, collaboration activities, andor other sources of capital.Key Anticipated 2020 Milestones NDA acceptancePDUFA date assignment for trilaciclib in SCLC in August 2020. Initiate Phase 3 clinical trial of trilaciclib in colorectal cancer in 4Q20. Presentation of Phase 2 data of trilaciclib in triple-negative breast cancer in 4Q20. Presentation of additional rintodestrant monotherapy data in 4Q20.Webcast and Conference Call The management team will host a webcast and conference call at 5:00 p.m. ET today to provide a corporate and financial update for the second quarter 2020 ended June 30, 2020. The live call may be accessed by dialing 866-763-6020 domestic or 210-874-7713 international and entering the conference code: 4648036. A live and archived webcast will be available on the Events Presentations page of the companys website: The webcast will be archived on the same page for 90 days following the event.About G1 Therapeutics G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader SERD for the treatment of ER breast cancer. Lerociclib is a differentiated oral CDK46 inhibitor designed to enable more effective combination treatment strategies.G1 Therapeutics is based in Research Triangle Park, N.C. 